
Cytiva is a global life sciences company and Cellular Origins, a TTP company, is focused on advancing scalable and cost-effective cell and gene therapy (CGT) manufacturing.
A combination of Cytiva’s Sefia automated platform and Cellular Origin’s Constellation automated robotic platform will enable CGT manufacturers to scale production to industrial levels. The two systems will seamlessly interface and provide a fully digital connection, enabling fully remote digital controls and analytics. By eliminating manual intervention between and within CGT production steps, new standards of automation and manufacturing productivity are being driven.
Manual labor
Edwin Stone, CEO of Cellular Origins, said: “The production of cell and gene therapies must evolve from personalized and small batch medicines to industrialization if these therapies are to reach more patients. At Cellular Origins, we are working to make this a reality. By partnering with Cytiva, a leading life sciences provider, we are building a unified automation platform that can meet the large-scale industrial needs of the sector.”
Current production of CAR-T therapies relies heavily on manual labor, adding to the complexity and variability of the processes. Meeting the growing demand from patients will be more difficult for pharmaceutical companies given the current limited production capacity, the significant risk of batch errors, and the expected increase in regulatory approvals for broader indications.
Robotic approach
Cytiva and Cellular Origins say a modular robotic approach will help manufacturers scale from thousands to hundreds of thousands of CGT doses per year. The combined solution will seamlessly integrate the two systems into existing customer workflows, enabling customers to produce commercially approved and late-stage CGT products 24/7 without changing systems or redesigning approved processes. Work is ongoing and the first systems will be ready for process and biological testing in early 2025. GMP systems are expected to be available for clinical use in late 2025.
Bron: Cytiva Life Sciences